Find a study
Browse recruiting studies near you — free to check, always your choice.
113 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Dementia / Alzheimer'sParkinson's disease
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
Testing whether a tributyrin supplement helps memory, thinking, and balance in adults with Parkinson
📍 Domino's Farms · Ann Arbor, MI · Get directions →
The goal of this clinical trial is to learn if taking a tributyrin supplement works to improve memory and thinking and walking and balance in adults with Parkinson disease Parkinson disease dementia. It will also learn about the safety of tributyrin supplementation.
- Multiple sclerosis (MS)
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Testing remibrutinib in people with relapsing multiple sclerosis who switch from ocrelizumab versus
📍 Perseverance Research Center · Scottsdale, AZ · +39 more US sites · Get directions →
The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).
- Dementia / Alzheimer's
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
Testing the safety and how a drug works in people with Alzheimer’s
📍 Clinical Trial Site · Montreal, · Get directions →
The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration
- Multiple sclerosis (MS)
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
Testing the safety and effects on disease and immune cells of one dose of YTB323 in people with
📍 Novartis Investigative Site · Darlinghurst, New South Wales · Get directions →
This is an open-label, multi-center, non-confirmatory study to assess the safety, disease progression, and cellular kinetics following YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort.
- Multiple sclerosis (MS)
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Testing a modified ublituximab treatment for relapsing multiple sclerosis
📍 TG Therapeutics Investigational Trial Site · Birmingham, AL · +34 more US sites · Get directions →
The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-blind, placebo-controlled, and Part C is single-armed and open-label.
- Multiple sclerosis (MS)
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Testing safety of a new immune cell therapy in adults with multiple sclerosis
📍 Research Site · Tucson, AZ · +8 more US sites · Get directions →
This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.
- Multiple sclerosis (MS)
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
Testing safety of a twice-yearly medicine for early relapsing MS
📍 Northwestern Memorial Hospital · Chicago, IL · Get directions →
In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months.
- Dementia / Alzheimer's
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Testing the safety and effects of two drugs for agitation in Alzheimer’s dementia
📍 Esperanza Clinical · Murrieta, CA · +8 more US sites · Get directions →
The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.
- Dementia / Alzheimer'sParkinson's disease
PET Imaging Evaluation of [11C]SY08
Testing a PET scan tracer to detect alpha-synuclein protein clumps in dementia and Parkinson’s
📍 MGH · Charlestown, MA · Get directions →
The overall goal of the proposed research is to evaluate the use of \[11C\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to evaluate the use of \[11C\]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls.
- Dementia / Alzheimer's
Rifaximin SSD in Dementia Trial
Testing a new form of rifaximin to change gut microbes in people with dementia
📍 Richmond VA Medical Center · Richmond, VA · Get directions →
Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.
- Multiple sclerosis (MS)
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Testing the safety and effects of KITE-363 in people with multiple sclerosis
📍 Stanford Neuroscience Health Center · Palo Alto, CA · +3 more US sites · Get directions →
This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases.
- Multiple sclerosis (MS)
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Testing whether combining a walking medication with physical therapy improves mobility in people
📍 MGH Institute of Health Professions · Boston, MA · Get directions →
The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine?
- Multiple sclerosis (MS)
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
Testing a CD19 CAR-T cell treatment for progressive multiple sclerosis
📍 Stanford Multiple Sclerosis Center · Palo Alto, CA · Get directions →
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis
- Dementia / Alzheimer's
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
Testing a gene therapy in people with a genetic form of frontotemporal dementia
📍 The Ohio State University (OSU) Wexner Medical Center · Columbus, OH · +2 more US sites · Get directions →
The goal of this clinical study is to learn about an investigational gene therapy product called AVB-101, which is designed to treat a disease called Frontotemporal Dementia with Progranulin Mutations (FTD-GRN). FTD-GRN is an early-onset form of dementia, a progressive brain disorder that affects behavior, language and movement.
- Dementia / Alzheimer's
SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy
Using brain scans to study how HIV affects the brain during treatment
📍 Yale School of Medicne, Neuro ID Research Program · New Haven, CT · Get directions →
The purpose of this study is to longitudinally characterize and evaluate changes in synaptic density in the brain using novel positron-emission tomography (PET) scans; magnetic resonance imaging (MRI), and clinical laboratory markers associated with HIV-related injury in the central nervous system. This study will test hypotheses relating to the presence and mechanisms of aberrant brain structure at the synaptic level in living humans with virologically controlled HIV on antiretroviral therapy.
- Dementia / Alzheimer's
Exploration of an Online Education Program to Support Caregivers' Knowledge Transfer
Testing an online program to help dementia caregivers share what they learn
📍 Texas Christian University · Fort Worth, TX · +1 more US site · Get directions →
The overarching goal of this work is to determine methods that improve caregiver education about the behavioral and psychological symptoms (BPSD) of dementia. The specific goal of this project is to extend our prior work to evaluate the impact of our educational intervention on caregivers' ability to transfer knowledge about the management of ADRD to real-world applied examples.
- Dementia / Alzheimer's
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Testing whether KarXT plus KarX-EC is safe and works for memory problems in Alzheimer’s disease
📍 Healthy Brain Clinic · Long Beach, CA · +27 more US sites · Get directions →
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Multiple sclerosis (MS)
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Testing a drug called orelabrutinib versus placebo in people with PPMS
📍 Arizona Neuroscience Research, LLC · Pheonix, AZ · +12 more US sites · Get directions →
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS.
- Dementia / Alzheimer's
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Testing long-term safety and effectiveness of two medicines for agitation in Alzheimer’s dementia
📍 Local Institution - 2609 · Chandler, AZ · +39 more US sites · Get directions →
The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.
- Multiple sclerosis (MS)
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Comparing stem cell transplant vs best available treatment for relapsing multiple sclerosis
📍 Stanford Multiple Sclerosis Center · Palo Alto, CA · +21 more US sites · Get directions →
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio.
- Dementia / Alzheimer's
Ferritin and Iron Burden in SAH sIRB
Testing how iron and ferritin levels relate to brain injury after ruptured aneurysms with dementia
📍 Univesity of Iowa Hospital and Clinics · Iowa City, IA · +1 more US site · Get directions →
Ruptured cerebral aneurysms lead to subarachnoid hemorrhage (SAH),that has a high morbidity and mortality rate, the severity of which is predicted by the "Hunt-Hess grade" (HHG). SAH leads to iron (Fe) and hemoglobin (Hb) accumulation in the brain, which is toxic for neurons.
- Dementia / Alzheimer's
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
Studying whether ovarian hormones are linked to aging and Alzheimer’s risk in women
📍 Mayo Clinic · Jacksonville, FL · +1 more US site · Get directions →
The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.
- Dementia / Alzheimer's
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Testing whether yearly donanemab helps people with dementia after a prior study
📍 Banner Alzheimer's Institute · Phoenix, AZ · +39 more US sites · Get directions →
The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.
- Multiple sclerosis (MS)
Entire-body PET Scans for Multiple Sclerosis
Testing whether whole-body PET scans can better track MS brain and nerve damage
📍 Brain Health Alliance · Ladera Ranch, CA · Get directions →
To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in multiple sclerosis (MS) patients.
- Multiple sclerosis (MS)
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Testing orelabrutinib versus placebo for people with non-active secondary progressive multiple
📍 Arizona Neuroscience Research, LLC · Phoenix, AZ · +12 more US sites · Get directions →
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS.
- Dementia / Alzheimer's
A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK
Testing a medicine in people with dementia to lower brain tau protein
📍 Washington University in St. Louis · St Louis, MO · Get directions →
This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells.
- Dementia / Alzheimer's
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
Testing a treatment called SNK01 in people with moderate Alzheimer’s disease
📍 Behavioral Research Specialists, LLC · Glendale, CA · +6 more US sites · Get directions →
The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: 1.
- Dementia / Alzheimer's
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Testing a drug called trontinemab for early Alzheimer’s disease dementia
📍 Banner Alzheimer?s Institute · Phoenix, AZ · +32 more US sites · Get directions →
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
- Multiple sclerosis (MS)
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
Testing how a new medicine given through a vein or under the skin is handled and tolerated in people
📍 Stanford University Medical Center · Stanford, CA · +4 more US sites · Get directions →
The primary purpose of the study is to evaluate the safety and tolerability of a single-ascending intravenous (IV) dose (Part 1), a single-ascending subcutaneous (SC) dose (Part 2), and multiple ascending SC doses (Part 3) of RO7121932 in participants with multiple sclerosis (MS).
- Multiple sclerosis (MS)
Home Based Infusions for Ocrelizumab
Testing the safety and effectiveness of home infusions of ocrelizumab for multiple sclerosis
📍 Amerita · Centennial, CO · Get directions →
The goal is to assess the safety and effectiveness of home ocrelizumab infusion.
- Multiple sclerosis (MS)
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Testing ozanimod versus fingolimod in children with multiple sclerosis
📍 Local Institution - 0114 · Loma Linda, CA · +11 more US sites · Get directions →
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
- Dementia / Alzheimer's
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Testing a treatment called KarXT plus KarX-EC for psychosis in people with Alzheimer's disease
📍 Gilbert Neurology Partners/CCT Research · Gilbert, AZ · +5 more US sites · Get directions →
The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.
- Multiple sclerosis (MS)
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Testing whether TRX319 is safe for people with progressive multiple sclerosis
📍 University of Kansas Medical Center · Kansas City, KS · +1 more US site · Get directions →
The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS. The main questions the trial aims to answer are the following: * Is TRX319 safe when administered to patients with progressive forms of MS?
- Multiple sclerosis (MS)
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Testing a new drug’s safety and effects in people with multiple sclerosis
📍 Local Institution - 0011 · Birmingham, AL · +16 more US sites · Get directions →
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).
- Dementia / Alzheimer'sMultiple sclerosis (MS)
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Testing how an imaging tracer works in people with memory loss and multiple sclerosis
📍 Yale University PET Center · New Haven, CT · Get directions →
The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
- DepressionDementia / Alzheimer's
Aβ Dynamics in LLMD
Testing how treating depression may change brain markers linked to Alzheimer’s
📍 NYU Langone Health · New York, NY · +1 more US site · Get directions →
This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and associated risk is to treat the depressive symptoms and examine the effects on AD biomarkers.
- Dementia / Alzheimer's
Epidemiology and Biomarker Study in Alzheimer's Disease
Studying how memory changes over time and blood test results in people with dementia
📍 Care Access - Houston · Houston, TX · Get directions →
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
- Dementia / Alzheimer's
Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease
Testing how a new medicine works in healthy adults and early Alzheimer’s disease
📍 Research Site 3 · East York, Ontario · Get directions →
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.
- Multiple sclerosis (MS)
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Testing how well and how safely remibrutinib works in secondary progressive multiple sclerosis
📍 Alabama Neurology Associates PC · Birmingham, AL · +32 more US sites · Get directions →
The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)
- Dementia / Alzheimer's
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
Testing whether a brain PET scan can predict worsening memory problems
📍 Endeavor Health Systems · Evanston, IL · Get directions →
CMK-0301 is a multi-site, randomized clinical trial to evaluate the safety and efficacy of \[F-18\]Flornaptitril-PET (F-18 FNT-PET) for the prediction of clinical progression of Mild Cognitive Impairment (MCI) with either Suspected Chronic Traumatic Encephalopathy (CTE) or Alzheimer's Disease (AD). The primary objectives of the study are to: (1) To determine the accuracy of F-18 FNT-PET in prediction of clinical decline and (2) To assess the safety and tolerability of F-18 FNT.
- Dementia / Alzheimer's
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Testing a treatment (KarXT plus KarX-EC) for memory problems in Alzheimer’s dementia
📍 Fullerton Neurology and Headache Center · Fullerton, CA · +29 more US sites · Get directions →
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Dementia / Alzheimer's
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
Testing time-limited eating to see if it improves sleep and brain changes in early Alzheimer’s or
📍 Shiley Marcos Alzheimer's Disease Center · San Diego, CA · Get directions →
The goal of this clinical trial is to learn if restricting the time of eating to allow for prolonged fasting at night may reduce sleep disturbances, cognitive decay, and pathology in patients diagnosed with Mild Cognitive Impairment (MCI) or early to moderate Alzheimer's disease (AD). It will also learn about the feasibility of practicing 14 h of nightly fasting in this group of older adults.
- Multiple sclerosis (MS)💵 May compensate
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
Testing whether ozanimod is safe and works as a step-down treatment for stable multiple sclerosis
📍 University of Colorado Anschutz Medical Campus · Aurora, CO · +2 more US sites · Get directions →
A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.
- Dementia / Alzheimer's
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
Comparing tau brain scan images in different types of dementia
📍 Perelman Center for Advance Medicine · Philadelphia, PA · Get directions →
The investigators will compare \[18F\]-PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched cognitively normal subjects.
- Dementia / Alzheimer's
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
Testing the safety and effects of ACI-24.060 in Alzheimer’s and Down syndrome
📍 Barrow Neurological Institute · Phoenix, AZ · +12 more US sites · Get directions →
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
- Dementia / Alzheimer's
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
Testing a drug combination to treat agitation in adults with Alzheimer’s
📍 Chandler Clinical Trials, LLC · Chandler, AZ · +39 more US sites · Get directions →
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
- Multiple sclerosis (MS)
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
Testing whether switching from ocrelizumab to ublituximab helps MS symptoms that return
📍 Johns Hopkins University · Baltimore, MD · Get directions →
The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.
- Dementia / Alzheimer's
Nicotinic Acid for the Treatment of Alzheimer's Disease
Testing how well extended-release niacin reaches spinal fluid in dementia
📍 IU Health Neuroscience Center · Indianapolis, IN · Get directions →
Increased dietary intake of niacin is correlated with reduced risk of Alzheimer's Disease and age-associated cognitive decline. The goal of this study is to collect data on the penetration of commercially available, FDA approved, extended-release niacin into the spinal fluid.
- Dementia / Alzheimer's
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
Testing whether a new drug is safe in people with early Alzheimer’s
📍 K2 Medical Research, LLC · Maitland, FL · +5 more US sites · Get directions →
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD.
- Dementia / Alzheimer's
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
Testing deep rTMS on a brain area for people with probable Alzheimer dementia to see if it is safe
📍 UCLA TMS Clinical and Research Service · Los Angeles, CA · Get directions →
The goal of this clinical trial is to learn if using deep repetitive transcranial magnetic stimulation (rTMS) targeting the precuneus is feasible, tolerable, and potentially efficacious for memory in Probable Alzheimer's Dementia. Previous work studying rTMS in Alzheimer's is mixed, but recent work studying rTMS of the precuneus is encouraging for both its short-term and long-term effects.
- Multiple sclerosis (MS)
Glucose Consumption in MS Using [F-18]FDG-PET
Testing how [F-18]FDG PET shows glucose use in people with MS and controls
📍 Brigham & Women's Hospital · Boston, MA · Get directions →
Given the need for better diagnostic imaging techniques in multiple sclerosis (MS), the study aims to investigate the utility of \[F-18\]FDG positron emission tomography (PET) in MS. The study will be assessing glucose consumption patterns in subjects with progressive MS (PMS) and relapsing-remitting MS (RRMS), as well as healthy controls.
- Dementia / Alzheimer's
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
Testing the safety and effects of ABBV-1758 in people with Alzheimer’s disease given as injections
📍 Irvine Center for Clinical Research /ID# 277752 · Irvine, CA · +10 more US sites · Get directions →
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness.
- Dementia / Alzheimer's
Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD)
Testing a rideshare with a trained driver to help people with dementia get to medical visits
📍 Onward Health HQ · San Leandro, CA · Get directions →
The goal of this pilot randomized controlled trial is to assess the impact of D2D rideshare services with a trained companion driver on the rate of medical appointments for older adults and individuals with AD/ADRD. Participants will be assigned either door-through-door (D2D) rideshare or curb-to-curb (C2C) rideshare services.
- Dementia / Alzheimer's
Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia
Testing an education and support group for people with progressive aphasia and their caregivers
📍 University of Texas at Austin · Austin, TX · Get directions →
The current study aims to examine the benefits of an education/support group program for individuals with progressive aphasia (caused by various etiologies, diagnoses) and their carepartners. The current study utilizes pre-, post-treatment, and follow-up assessments to measure effects of a psychoeducational support group and an implementation/communication skills training phase on measures of psychosocial function, communicative effectiveness and speech/language function.
- Multiple sclerosis (MS)
Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis
Testing whether silodosin helps lower urinary tract symptoms in women with multiple sclerosis
📍 Atlantic Health · Morristown, NJ · Get directions →
The goal of this clinical trial is to learn if silodosin works to treat lower urinary tract symptoms (LUTS) in female patients with multiple sclerosis (MS). It will also learn about the effect of the drug on voiding parameters.
- Multiple sclerosis (MS)
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
Testing whether obe-cel is safe and has early effects in adults with progressive multiple sclerosis
📍 Stanford University · Redwood City, CA · Get directions →
The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The study also plans to assess if obe-cel can show early signs of efficacy in MS.
- Dementia / Alzheimer's
Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease
Testing whether rTMS affects memory and brain function in dementia
📍 Massachusetts General Hospital · Boston, MA · Get directions →
In this research study we want to learn more about the effects of non-invasive brain stimulation on memory and brain-network function in cognitively unimpaired older adults and in patients with amnestic mild cognitive impairment (aMCI). This study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS).
- Dementia / Alzheimer's
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
Testing the safety and side effects of Zunveyl in people with mild to moderate Alzheimer’s
📍 Tekton Research Saint Louis Psychiatry · St Louis, MO · Get directions →
The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.
- Multiple sclerosis (MS)
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
Testing whether clemastine fumarate changes MRI signs of nerve repair in people with multiple
📍 Sandler Neurosciences Building, Neurological Clinical Research Unit · San Francisco, CA · Get directions →
The clinical trial is intended to assess for clinical evidence of Clemastine Fumarate as a myelin repair therapy in patients with chronic inflammatory injury-causing demyelination as measured by multi-parametric MRI assessments. No reparative therapies exist for the treatment of multiple sclerosis.
- Multiple sclerosis (MS)
Non-invasive Electrical Spinal Cord Stimulation To Restore Upper Extremity Function in Multiple Sclerosis
Testing non-surgical electrical stimulation to improve arm function in people with multiple
📍 University of Washington · Seattle, WA · Get directions →
Current disease-modifying therapies for multiple sclerosis (MS) aim to prevent the development of new lesions; unfortunately, no current FDA-approved therapies promote central nervous system (CNS) repair mechanisms. Thus, strategies to promote functional recovery from lesion-related deficits in adults with MS remain an unmet need.
- Showing the first 60 of 113. Add filters or a location to narrow down.